Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Significant Increase in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 287,608 shares, a growth of 61.5% from the August 31st total of 178,126 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average trading volume of 652,899 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

MBRX has been the topic of several research reports. HC Wainwright decreased their price target on shares of Moleculin Biotech to $3.00 and set a “buy” rating on the stock in a research note on Friday, August 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Finally, Wall Street Zen raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.00.

Moleculin Biotech Trading Up 0.7%

Shares of MBRX opened at $0.50 on Friday. The stock’s fifty day simple moving average is $0.72 and its 200 day simple moving average is $1.85. The firm has a market capitalization of $9.81 million, a P/E ratio of -0.07 and a beta of 2.00. Moleculin Biotech has a twelve month low of $0.16 and a twelve month high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.55) by $0.15. Sell-side analysts predict that Moleculin Biotech will post -2.37 earnings per share for the current year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancers that are difficult to treat or have limited therapeutic options. The company’s research programs target cancer-cell survival mechanisms, drug resistance and tumor metabolism.

Moleculin’s lead product candidate is annamycin, a liposomal formulation of doxorubicin designed to retain anticancer activity while reducing the risk of cardiotoxicity associated with some conventional anthracyclines.